EXAI News and Press, Exscientia Limited From 09/20/23

2023-09-20 10:11:33 ET DENVER, Colo., Sept 20, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Genius Group (NYSEAMERICAN:GNS), Steelcase (NYSE:SCS), Fresh Tracks Therapeutics (NASDAQ:FRTX), Exscientia (N...

2023-09-20 08:32:17 ET (24/7 MARKET NEWS) – Exscientia plc (NASDAQ:EXAI) introduced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology, utilizing Exscientia’...

2023-09-20 07:47:47 ET More on Exscientia and AI drug discovery Seeking Alpha’s Quant Rating on Exscientia Exscientia Is Worth The AI-Driven Speculation Exscientia gains as enrollments begin for cancer trial AI to represent 11% of healthcare budgets in...

Collaboration will leverage Exscientia’s precision design capabilities to focus on previously unsolved drug design challenges Exscientia is eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones for three projects, in addition to sin...

2023-09-15 08:45:00 ET The potential for artificial intelligence (AI) to be used as a tool for better drug discovery is already obvious. AI can help in patient recruitment, better trial design, predictive analytics, and data analysis. Simply put, it can help cut the time that it takes t...

2023-09-04 12:00:00 ET More on AI Cathie Wood's 'Big Ideas 2023' sees Artificial Intelligence as the future Artificial intelligence is a '1995 moment' for tech. That could push stocks even higher Apple CEO Tim Cook says artificial intelligence 'is a major focus of ou...

2023-08-28 17:17:30 ET Gainers: Fate Therapeutics ( NASDAQ: FATE ) +5% . Diversified Healthcare  ( DHC ) +4% . Taysha Gene Therapies ( TSHA ) +3% . Afya ( AFYA ) +3% . Iris Energy ( IREN ) +2% . Losers: Kodiak Sc...

2023-08-10 12:37:09 ET Exscientia plc (EXAI) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Mike Krams - Chief Quantitative Medicine Off...

2023-08-10 07:20:38 ET Exscientia press release ( NASDAQ: EXAI ): Q2 GAAP EPS of -$0.37 beats by $0.09 . Revenue of $3.8M (-58.2% Y/Y) misses by $4.55M . For further details see: Exscientia GAAP EPS of -$0.37 beats by $0.09, revenue of $3.8M misses by $4.55M

Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:3...